Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
New HIV treatment options for children and adolescents in Africa
PACTR202608701169078Phase 3Not yet recruiting
- Sponsor
- University College London
- Start
- Nov 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised trial of dolutegravir, abacavir, lamivudine, tenofovir alafenamide, emtricitabine and 4 more in human immunodeficiency virus infection (HIV) (5 arms), sponsored by University College London. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
dolutegravirabacavirlamivudinetenofovir alafenamideemtricitabine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202608701169078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202608701169078.